ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 127 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,450,000 | -73.0% | 500,000 | +46.5% | 0.05% | -68.2% |
Q4 2022 | $5,374,514 | +0.1% | 341,239 | 0.0% | 0.15% | -3.2% |
Q3 2022 | $5,371,000 | +12.7% | 341,239 | 0.0% | 0.16% | +4.7% |
Q2 2022 | $4,764,000 | -27.9% | 341,239 | -11.0% | 0.15% | +12.9% |
Q1 2022 | $6,607,000 | -70.9% | 383,239 | -75.5% | 0.13% | -24.6% |
Q4 2021 | $22,718,000 | +61.6% | 1,562,472 | +100.0% | 0.18% | -14.2% |
Q3 2021 | $14,062,000 | -52.9% | 781,236 | -54.0% | 0.20% | +5.2% |
Q2 2021 | $29,852,000 | +82.2% | 1,700,000 | +161.5% | 0.19% | -6.3% |
Q1 2021 | $16,380,000 | -56.4% | 650,000 | -48.4% | 0.21% | -90.3% |
Q1 2017 | $37,598,000 | +9.9% | 1,260,847 | 0.0% | 2.14% | -12.0% |
Q4 2016 | $34,219,000 | +210.7% | 1,260,847 | +193.2% | 2.43% | +242.2% |
Q3 2016 | $11,012,000 | – | 430,000 | – | 0.71% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |